March 23, 2013 at 07:16 AM EDT
Week in Review: BGI’s CEO Says Science Drives Collaborations
In an exclusive ChinaBio® Today interview, Dr. Jun Wang, CEO of BGI, said the sequencing company is “dream-driven,” always seeking to fulfill the promise of genomic science; BGI closed its $118 million acquisition of US-based Complete Genomics last week; Roche Holding stepped up as one of the bidders for lab equipment-maker Life Technologies; Hony Capital will support Simcere’s $506 million management-led privatization offer; OriGene of Maryland raised $21.3 million in a funding led by two China-focused venture funds; BGI and H3 Biomedicine of Cambridge will collaborate to sequence pre-clinical cancer models; Lilly officially opened the Lilly Global IT Innovations Lab in Dalian; Taiwan Liposome’s innovative liver cancer drug was accepted into the SFDA’s Green Path program; Amoy Diagnostics, a Xiamen IVD company, was OK’d to market a test for genetic abnormalities that affect lung cancer treatment; and Antisense of Australia will have Pharmaron conduct a toxicology study of its multiple sclerosis drug candidate. More details…. Stock Symbols: (VX: ROG) (NSDQ: LIFE) (NYSE: SCR) (NYSE: LLY) (TW: 4152) (ASX: ANP) Share this with colleagues: // //  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here